The DE-RADIATE study: protocol for a prospective, non-randomised biomarker-directed phase II study of 18F-FMISO PET-guided radical radiation dose de-escalation in HPV-associated oropharyngeal squamous cell carcinoma

Abstract Background HPV-associated oropharyngeal squamous cell carcinoma (HPV OPSCC) has excellent cure rates with standard high-dose radiation therapy (RT) and chemotherapy, but this comes at the cost of substantial long-term toxicity. De-escalation strategies aim to preserve oncologic outcomes while reducing treatment-related morbidity, with ¹⁸F-FMISO PET/CT emerging as a promising biomarker to guide patient selection based on tumour hypoxia. This study builds on prior pilot data to evaluate the feasibility and efficacy of ¹⁸F-FMISO-guided RT de-escalation in an independent healthcare setting and a distinct patient population. Methods DE-RADIATE is a phase II, non-randomised, uncontrolled, single institution prospective interventional study evaluating 18 F-FMISO PET-guided RT de-escalation in patients with AJCC 7th edition clinical stage T1-2N1-2b HPV OPSCC or squamous cell carcinoma of unknown primary of presumed mucosal origin (corresponding to ipsilateral nodal disease ≤ 6 cm, typically cT1-2N1M0 disease per AJCC 8th edition). After surgical resection of primary tumour, patients will commence RT. Patients will undergo 18 F-FMISO PET prior to RT and after two weeks of RT. Patients will be eligible for RT de-escalation (total prescribed dose 30 Gy in 15 fractions) in the absence of hypoxia on intra-treatment PET (irrespective of baseline hypoxia status). Remaining patients will receive standard of care RT to 70 Gy. All patients in both cohorts will receive concurrent platinum-based chemotherapy. Patients in the de-escalated cohort (Cohort A) will undergo neck dissection four months after RT to assess treatment response. Primary endpoint is pathologic complete response rate at neck surgery. Secondary endpoints include locoregional failure​, overall- and progression-free survival, toxicities, patient-reported quality of life, and correlation of hypoxic regions on 18 F-FMISO PET with oxygen-enhanced MRI. Conclusion The results will inform the design of larger prospective trials of hypoxia-guided RT de-escalation and may help identify patients most likely to benefit from reduced RT exposure.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-17
DOI
https://doi.org/10.1186/s12885-026-17290-7
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The DE-RADIATE study: protocol for a prospective, non-randomised biomarker-directed phase II study of 18F-FMISO PET-guided radical radiation dose de-escalation in HPV-associated oropharyngeal squamous cell carcinoma

Tricia Saurine, David Veivers, Alexander David Guminski, James Drummond et al.
2 links
BMC Cancer
Head and Neck Cancer Studies
article

The DE-RADIATE study: protocol for a prospective, non-randomised biomarker-directed phase II study of 18F-FMISO PET-guided radical radiation dose de-escalation in HPV-associated oropharyngeal squamous cell carcinoma

Tricia Saurine, David Veivers, Alexander David Guminski, James Drummond, Anna K. Lawless, Sarah Bergamin, Leba Michael Sarkis, Michael Back, Dasantha T. Jayamanne, Leo Pang, Rick Wray, Thomas Eade, Adrian Lee, Caterina Brighi, Geoffrey Paul Schembri, Andrew C. Wignall, Lisa M. Parker, Christopher Brown, Nancy Lee, Heiko Schöder, Dale Bailey
article en

Abstract

Abstract Background HPV-associated oropharyngeal squamous cell carcinoma (HPV OPSCC) has excellent cure rates with standard high-dose radiation therapy (RT) and chemotherapy, but this comes at the cost of substantial long-term toxicity. De-escalation strategies aim to preserve oncologic outcomes while reducing treatment-related morbidity, with ¹⁸F-FMISO PET/CT emerging as a promising biomarker to guide patient selection based on tumour hypoxia. This study builds on prior pilot data to evaluate the feasibility and efficacy of ¹⁸F-FMISO-guided RT de-escalation in an independent healthcare setting and a distinct patient population. Methods DE-RADIATE is a phase II, non-randomised, uncontrolled, single institution prospective interventional study evaluating 18 F-FMISO PET-guided RT de-escalation in patients with AJCC 7th edition clinical stage T1-2N1-2b HPV OPSCC or squamous cell carcinoma of unknown primary of presumed mucosal origin (corresponding to ipsilateral nodal disease ≤ 6 cm, typically cT1-2N1M0 disease per AJCC 8th edition). After surgical resection of primary tumour, patients will commence RT. Patients will undergo 18 F-FMISO PET prior to RT and after two weeks of RT. Patients will be eligible for RT de-escalation (total prescribed dose 30 Gy in 15 fractions) in the absence of hypoxia on intra-treatment PET (irrespective of baseline hypoxia status). Remaining patients will receive standard of care RT to 70 Gy. All patients in both cohorts will receive concurrent platinum-based chemotherapy. Patients in the de-escalated cohort (Cohort A) will undergo neck dissection four months after RT to assess treatment response. Primary endpoint is pathologic complete response rate at neck surgery. Secondary endpoints include locoregional failure​, overall- and progression-free survival, toxicities, patient-reported quality of life, and correlation of hypoxic regions on 18 F-FMISO PET with oxygen-enhanced MRI. Conclusion The results will inform the design of larger prospective trials of hypoxia-guided RT de-escalation and may help identify patients most likely to benefit from reduced RT exposure.

BMC Cancer
The University of Sydney (AU), Memorial Sloan Kettering Cancer Center (US), Royal North Shore Hospital (AU), Northern Sydney Local Health District (AU), Fondazione Politecnico di Milano (IT), NSW Health Pathology (AU), Politecnico di Milano (IT)
Royal Australian and New Zealand College of Radiologists
Good health and well-being
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon